Oaktree Specialty Lending Corporation
NASDAQ:OCSL · NASDAQ Global Select
-$0.04 today
Vol 0.80M · Avg 0.89M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
2.3%
avg 2.8%
ROIC
4.9%
avg 1.8%
ROA
1.1%
avg 1.5%
Analysis
ROIC is currently the strongest return metric at 4.9% versus its period average of 1.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Aman Kumar | Managing Director & Co-Portfolio Manager of Life Sciences Direct Lending | — | — | 45 | — | — |
Armen Panossian | Chief Executive Officer & Co-Chief Investment Officer | — | — | 50 | $20,789.00 | 0.02% |
Brett McKeone | Chief Operating Officer | — | — | — | $0.00 | <0.01% |
Christopher McKown | CFO & Treasurer | — | — | 44 | $5,092.00 | <0.01% |
Dane Kleven | Senior Vice President & Head of Investor Relations | — | — | — | — | — |
Mathew Pendo | President | — | — | 62 | $52,596.00 | 0.06% |
Raghav Khanna | Co-Chief Investment Officer | — | — | 42 | $6,000.00 | <0.01% |
Sandeep Kumar Khorana | Managing Director of Origination | — | — | 53 | $2,500.00 | <0.01% |
Ashley Pak | Chief Compliance Officer | — | — | 48 | $1,920.25 | <0.01% |
Mary Gallegly | MD,General Counsel & Secretary | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$122,309.25
Sells
0
$0.00
Net Sentiment
+$122,309.25
Net buying
Most Active
CALDWELL PHYLLIS R
4 transactions
Analysis
Insiders reported 6 buys worth $122,309.25 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $122,309.25. CALDWELL PHYLLIS R was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -53.1% | +12.4% (13yr)2 analysts |
| Revenue | N/A | N/A | -8.2% | +9.5% (13yr)2 analysts |
| Net Income | N/A | N/A | -42.1% | +17.0% (13yr)2 analysts |
| EBIT | N/A | N/A | -42.1% | +18.7% (13yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at -8.2% over three years. Forward estimates point to EBIT at +18.7% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
EZCORP, Inc.
NASDAQ:EZPW
$1.83B
Capital Southwest Corporation
NASDAQ:CSWC
$1.42B
ProAssurance Corporation
NYSE:PRA
$1.27B
Prospect Capital Corporation
NASDAQ:PSEC
$1.11B
Goldman Sachs BDC, Inc.
NYSE:GSBD
$1.04B
Jefferson Capital, Inc. Common Stock
NASDAQ:JCAP
$959.57M
Barings BDC, Inc.
NYSE:BBDC
$865.40M
MidCap Financial Investment Corporation
NASDAQ:MFIC
$815.90M
Navient Corporation
NASDAQ:NAVI
$764.60M
Lufax Holding Ltd
NYSE:LU
$547.15M
Who manages OCSL?
Oaktree Specialty Lending Corporation (OCSL) lists 10 active executives. The top listed executive is Aman Kumar, Managing Director & Co-Portfolio Manager of Life Sciences Direct Lending.
Are OCSL insiders buying or selling?
Recent insider activity shows net selling of $28.20M.
Explore More
Continue the stock analysis
Jump to another research area for this company.